Nasopharynx Cancer Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against nasopharynx cancer and guarantee the finest results for our customers all over the world.

Nasopharynx Cancer

Nasopharynx cancer, also known as nasopharyngeal carcinoma (NPC), is the most common form of cancer originating in the nasopharynx, which is most commonly found in the posterior nasopharyngeal or pharyngeal recess, accounting for 50%. Nasopharynx cancer occurs in both children and adults and is most common among men. It is more common in some parts of East Asia and Africa than elsewhere. Viral, diet and genetic factors are related to their etiology. The causes, occurrence, clinical manifestations and treatment are significantly different with nasopharynx cancer and other head and neck cancer. Neck lymph node enlargement is the first presentation in many people, and the diagnosis of nasopharyngeal carcinoma is often made by lymph node biopsy. Nasopharyngeal cancer can be treated by surgery, chemotherapy or radiotherapy. The expression of EBV latent protein in undifferentiated nasopharyngeal cancer can potentially be used for immune-based therapies.

Therapeutic Vaccines for Nasopharynx Cancer

Nasopharyngeal carcinoma is associated with the Epstein-Barr virus (EBV) and characterized by peritumoral immune infiltrate. Knowledge of the integral involvement of Epstein-Barr virus (EBV) in the pathogenesis of undifferentiated NPC has been of seminal importance in developing strategies to optimize disease management. In NPC, the EBV virus expresses a type II latency program and is present in virtually all poorly differentiated and undifferentiated nonkeratinizing (WHO type II and III) NPC. The close association with EBV is being evaluated in multiple settings including screening of at-risk populations, disease prognostication, development of targeted therapies, optimizing adjuvant treatment, and early recurrence detection. These translational studies are likely to have an enormous effect on management of undifferentiated NPC and significantly improve the landscape of the disease in years to come.

Therapeutic cancer vaccines for NPC have historically targeted EBV antigens. Autologous monocyte-derived dendritic cells cultured from patients with NPC and matured with cytokines were pulsed with HLA-A1101, A2402, or B40011 restricted epitope peptides from EBV-LMP2 and injected into inguinal lymph nodes. This strategy generated an expansion in the LMP2-specific response in the peripheral blood in the majority of patients, and a partial clinical response in the patients was seen. A more recent Phase II study evaluated the use of dendritic cells transduced with an adenovirus-DeltaLMP1- LMP2 vector given as five biweekly intradermal injections to sixteen heavily pretreated stage 4c NPC patients. This first-in-human study demonstrated the safety of this strategy. Another clinical trial using the MVAEL vaccine has provided evidence for the effectiveness of the direct administration of a poly-specific vaccine to generate LMP/EBNA1-specific CTL responses in patients. This recombinant vaccinia virus–based vaccine, which encodes a functionally inactive fusion protein containing the CD4 epitope-rich C-terminal half of EBNA1 and CD8 epitope-rich LMP2A could induce T-cell response in 80% of patients, in some cases boosting response to both CD4⁺ and CD8⁺ mediated immunity against EBNA1 and/or LMP2.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the nasopharynx cancer vaccines and dendritic cells vaccines. If you are interested in our services, please contact us for more details.

Reference

1. Jain, A. (2016). “Immunotherapy for nasopharyngeal cancer-a review.” Chin Clin Oncol 5(2), 22.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.